Navidea Biopharmaceuticals Inc (NAVB)


Stock Price Forecast

Nov. 3, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Navidea Biopharmaceuticals Inc chart...

About the Company

navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de

CEO

Jed Latkin

Exchange

OTC MARKETS

Website

https://www.navidea.com/

$0M

Total Revenue

13

Employees

$5M

Market Capitalization

-0.14

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $NAVB News

Navidea Biopharmaceuticals gets grant for method for conjugating metal chelating agent to functionalized dextran

1d ago, source: Pharmaceutical Technology

Discover Navidea Biopharmaceuticals Inc's innovative patent for conjugating metal chelating agents to dextran, free of crosslinking. Explore its potential in medical imaging and drug delivery.

Navidea Biopharmaceuticals, Inc. (NAVB)

3d ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Sarah Kathryn Rouan's Net Worth

22d ago, source: Benzinga.com

This is based on reported shares across multiple companies, which include Viking Therapeutics, Inc., and NAVIDEA BIOPHARMACEUTICALS, INC..

Navidea Biopharma (NAVB) Earnings Dates & Reports

24d ago, source: Investing

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session

1y ago, source: Hosted on MSN

GlucoTrack, Inc. (NASDAQ: GCTK ... with high cross-reactivity to multiple strains of influenza. Navidea Biopharmaceuticals (NASDAQ: NCMI) fell 17.5% to $0.3526. The company recently filed a ...

Navidea Biopharmaceuticals Inc NAVB

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Navidea Biopharmaceuticals Inc NAVB

15d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Navidea Biopharmaceuticals, Inc. (NAVB)

4mon ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Navidea Biopharmaceuticals, Inc (NAVB)

23d ago, source: Yahoo Finance

*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Navidea Biopharmaceuticals, Inc. (NAVB)

11mon ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...